Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (19)

2024

  1. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 2, pp. 223-230

2023

  1. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2022

  1. Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 1

2021

  1. A novel class of fast-acting antimalarial agents: Substituted 15-membered azalides

    British Journal of Pharmacology, Vol. 178, Núm. 2, pp. 363-377

2017

  1. European Respiratory Society guidelines for the management of adult bronchiectasis

    European Respiratory Journal, Vol. 50, Núm. 3

2012

  1. Design, synthesis, and in vitro activity of novel 2′- O -substituted 15-membered azalides

    Journal of Medicinal Chemistry, Vol. 55, Núm. 7, pp. 3216-3227

  2. Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents

    European Journal of Medicinal Chemistry, Vol. 49, pp. 365-378

2011

  1. Four year immunogenicity of the RTS,S/AS02 A malaria vaccine in Mozambican children during a phase IIb trial

    Vaccine, Vol. 29, Núm. 35, pp. 6059-6067

2008

  1. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials

    Journal of Medicinal Chemistry, Vol. 51, Núm. 9, pp. 2845-2852

2007

  1. Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth

    Bioorganic and Medicinal Chemistry Letters, Vol. 17, Núm. 10, pp. 2740-2744

2003

  1. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836

2001

  1. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential

    Toxicology in Vitro

2000

  1. A proteomic approach for the study of Saccharomyces cerevisiae cell wall biogenesis

    Electrophoresis

  2. Cross-species identification of novel Candida albicans immunogenic proteins by combination of two-dimensional polyacrylamide gel electrophoresis and mass spectrometry

    Electrophoresis, Vol. 21, Núm. 13, pp. 2651-2659

  3. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: The impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics

    Journal of Antimicrobial Chemotherapy, Vol. 46, Núm. 4, pp. 557-564

1999

  1. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 2, pp. 357-359

  2. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 1, pp. 178-180

  3. Sin1: An evolutionarily conserved component of the eukaryotic SAPK pathway

    EMBO Journal, Vol. 18, Núm. 15, pp. 4210-4221

1997

  1. Microplate assays for in vitro evaluation of anti-Pneumocystis drugs

    Journal of Eukaryotic Microbiology